Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?

E-ISSN： 1876-1038|11|2|81-86

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.11, Iss.2, 2016-06, pp. : 81-86

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Docetaxel in Combination with Dacarbazine in Patients with Advanced Melanoma

Oncology, Vol. 63, Iss. 4, 2002-11 ,pp. : 333-337

Karger

Access to resources Recommend Favorite

Melanoma: The Radiotherapeutic Point of View; Review of the Current Literature

Reviews on Recent Clinical Trials, Vol. 6, Iss. 2, 2011-05 ,pp. : 127-133

Bentham Science Publishers

Access to resources Recommend Favorite

Immune checkpoint inhibitors: new strategies to checkmate cancer

CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 191, Iss. 2, 2018-02 ,pp. : 133-148

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dacarbazine, Nimustine Hydrochloride, Cisplatin and Tamoxifen Combination Chemotherapy for Advanced Malignant Melanoma

THE JOURNAL OF DERMATOLOGY, Vol. 26, Iss. 8, 1999-08 ,pp. : 489-493

John Wiley & Sons Inc

Access to resources Recommend Favorite

Preliminary Results of the Combination of Bevacizumab and Weekly Paclitaxel in Advanced Melanoma

Oncology, Vol. 74, Iss. 1-2, 2008-06 ,pp. : 12-16

Karger

Access to resources Recommend Favorite